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Abstract
Clostridium difficile has become an increasingly common infectious agent in the healthcare 
setting. It is generally associated with antibiotic use and causes diarrhea as well as other 
complications such as pseudomembranous colitis (PMC) and toxic megacolon. This organ-
ism poses a serious threat to patients in the intensive care unit (ICU) as it increases hospital 
length of stay, morbidity, and mortality. Recurrence rates are typically higher in the ICU 
population as those patients usually have immunocompromised systems, more exposure 
to antibiotics and proton pump inhibitors, loss of normal nutritional balance, and altera-
tions in their colonic flora. Emergence of more virulent and pathogenic strains has made 
combating the infection even more difficult. Newer therapies, chemotherapeutic agents, 
and vaccinations are on the horizon. However, the most effective treatments to date are 
ceasing the inciting agent, reduction in the use of proton pump inhibitors, and prevention 
of the disease. In this chapter, we will explore the risk factors, diagnosis, treatment, and 
prevention of C. difficile infections (CDI) in the ICU.
Keywords: Clostridium difficile, intensive care unit, pseudomembranous colitis, toxic 
megacolon, NAP1
1. Introduction
Clostridium difficile is a gram-positive, spore forming anaerobic bacillus that can survive on 
environmental surfaces for years in the spore (dormant) stage. First cultured in 1935 by Hall 
and O’Toole, C. difficile was a relatively unknown organism until 1978 [1]. It was initially 
thought to be a mostly harmless colonizer of the human intestinal tract. In 1893, a young 
woman died after gastric surgery from a “diphtheric colitis” as described by John Finney and 
Sir William Osler [2]. In 1978, Dr. John G. Bartlett determined that C. difficile was associated 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
with the ailment that had killed the young woman 85 years prior and was now termed pseu-
domembranous colitis (PMC) [3].
C. difficile is currently the most common cause of antibiotic-associated pseudomembranous coli-
tis in the healthcare setting and caused 20–30% of those with uncomplicated antibiotic-associ-
ated diarrhea [4]. According to the Centers for Disease Control, the number of cases of C. difficile 
infections (CDIs) in patients discharged from acute-care facilities doubled from 149,000 to 
300,000 between 2001 and 2005 and based on recent trends has reached nearly 500,000 cases per 
year [5, 6]. There are occasionally other causes of antibiotic associated colitis due to organisms 
such as Staphylococcus aureus, Klebsiella oxytoca, enterotoxin-producing strains of Clostridium per-
feringens, or Salmonella [7]. Treatment duration for most microbial infections is usually around 14 
days but prolonged exposure to broad-spectrum antibiotics has been associated with increased 
rates of both initial C. difficile infection and recurrence of C. difficile infection [8, 9].
The damage caused by C. difficile is due to the ability of the microbe to attach to the mucosa 
of the colon and release of exotoxins into the mucosa. The toxins may cause diarrhea, dilation 
of the colon (toxic megacolon), (Figure 1) sepsis, and death. Transmission is person to person 
via the fecal-oral route with ingestion of spores that germinate into vegetative bacteria within 
the small intestine. C. difficile produces two toxins—toxins A and B. These are large proteins 
(308 and 270 kDa, respectively) that cause severe inflammation and necrosis of the mucosal 
tissue by inactivating Rho, Rac, and Cdc42 targets within the epithelial cells through irrevers-
ible glycosylation [10, 11]. Toxin B is thought to be a gene duplication event of toxin A but is 
10 times more cytotoxic than toxin A [12, 13].
The bacteria are normally found in up to 25% of hospitalized adults and up to 70% of the 
hospitalized pediatric population [14]. It does not cause disease until the normal flora is dis-
rupted and C. difficile is allowed to proliferate. C. difficile infection has a very high  economic cost 
Figure 1. Toxic megacolon related to Clostridium difficile infection. Credit: University of Pittsburgh Department of Pathology.
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 associated with it in the United States and Europe due to high reinfection rates of approximately 
30% and risk of relapse of 60% producing over 900,000 cases and an estimated $1.1–$3.2 billion 
per annum burden [15, 16].
Antibiotic therapy that disrupts the normal flora are usually to blame but proton pump 
inhibitors and other gastric acid suppression medications are increasingly associated with 
increases in C. difficile overgrowth [17]. Although the cephalosporin class, clindamycin, and 
the fluoroquinolones are all thought to place a patient at a higher risk of infection, all antibi-
otics, including oral vancomycin and metronidazole, can induce pseudomembranous colitis 
due to their ability to eliminate most normal intestinal flora in combination with the increased 
resistance patterns of more virulent strains of C. difficile [3, 14, 18, 19] The NAP1 strain is par-
ticularly important as it is associated with fluoroquinolone use and has risen in incidence in 
Canada, Europe, and the United States with increased virulence, toxin production, mortality, 
treatment failures, and relapse [20, 21].
The incidence and virulence of this pathogen has been steadily increasing over the last sev-
eral decades contributing to higher morbidity and mortality. The increasingly older patient 
population with its higher acuity of medical issues and immunosenescence, the increased 
use of proton pump inhibitors, and the continued use of antibiotics has all allowed C. dif-
ficile to leave a greater impact in healthcare settings. In this chapter, we will explore the risk 
factors, diagnosis, treatment, and prevention of C. difficile infections in the intensive care 
unit (ICU).
2. A historical perspective on Clostridium difficile
Pseudomembranous colitis became a common complication of antibiotic use in the 1950s at 
the beginning of the antibiotic era and was found often in postoperative patients with an 
incidence of 14–27% [22, 23]. S. aureus was the suspected pathogen and standard treatment 
became oral vancomycin [24].
Tedesco et al. described “clindamycin colitis” in 1974 utilizing culture and endoscopy to 
diagnose pseudomembranous colitis associated with antibiotic use after 21% of patients 
given clindamycin developed diarrhea and 10% developed pseudomembranous colitis [25]. 
Incidentally, S. aureus did not grow from stool cultures from any of the patients. This study, 
more than prior publications, crystallized the connection between antibiotic use and devel-
opment of pseudomembranous colitis. Green, while studying penicillin-induced death in 
guinea pigs in 1974 described stool cytopathic changes that he attributed to the activity of a 
latent virus. In retrospect, this appears to be the first identification of the effects of C. difficile 
cytotoxin [26]. Between 1977 and 1979, using hamster models, multiple teams of researchers 
identified C. difficile as the causative agent of pseudomembranous colitis, including detecting 
toxin B produced by C. difficile [27–30]. “Clindamycin colitis” became known as “antibiotic-
induced colitis” and most of the studies done in the 1980s demonstrated that cephalosporins 
were the most frequently implicated agents followed secondly by broad-spectrum penicillins, 
including amoxicillin [30–33].
Clostridium difficile in the ICU
http://dx.doi.org/10.5772/intechopen.69212
131
Although there are many causes of pseudomembranous colitis, the majority of cases since the 
late 1970s have been caused by C. difficile infection. Pseudomembranous colitis is limited to the 
proximal colon in 20–30% of cases and may therefore be missed by sigmoidoscopy, providing 
more credence to performing a complete colonoscopy to identify anatomic lesions [25, 34]. 
With the current availability of C. difficile toxin assays, colonoscopy is rarely necessary. The 
first test used to diagnose C. difficile involved neutralization of the cytotoxin by C. sordellii 
antitoxin. This remains the most sensitive and specific diagnostic test, but is expensive and 
requires 24–48 hours for results [35] that has led to the development of latex particle agglu-
tination [36–38], dot immunoblot [39], PCR [40, 41], stool culture on selective media [42, 43], 
and enzyme immunoassay (EIA) [44, 45]. Because of differences between the hamster model 
and humans, it was originally believed that toxin A was important in human disease and 
many early EIA tests only detected toxin A, leading to false negative tests [46, 47].
3. Clinical signs and symptoms
Watery diarrhea with a distinct odor is usually the hallmark of C. difficile infection. Mild 
disease consists of crampy, watery diarrhea without systemic symptoms. This cohort con-
stitutes 70% of patients with C. difficile infection as only about 30% of patients with C. difficile 
infection are febrile and 50% have a leukocytosis [48]. In severe disease, fecal leukocytes 
are generally high and diagnosis can be confirmed with endoscopy demonstrating pseudo-
membranous colitis. Other signs and symptoms of severe disease include abdominal pain, 
leukocytosis, and fever or other systemic symptoms. Leukocytosis is directly correlated 
with the severity of the disease. The elevation in white blood cell count can be as mar-
ginal as 15,000 cells/mL or as high as 50,000 cells/mL. Complications may include paralytic 
ileus, toxic megacolon, or other life threatening conditions. Postoperative patients and other 
patients with altered gastrointestinal motility may have pseudomembranous colitis without 
diarrhea secondary to ileus. Computed tomography is useful with characteristics of colitis 
readily seen on imaging that may include colonic wall thickening and associated ascites or 
toxic megacolon [21, 49].
Patients in the ICU tend to demonstrate the same spectrum of disease signs and symptoms 
as other infected persons. However, due to their illnesses, comorbidities weakened immune 
system and reduced ability to heal; the progression of the disease may advance more rapidly. 
Therefore, continual assessment of diarrhea and other symptoms of C. difficile infection is 
necessary as the severity may progress and further impact the already impaired and critical 
status of the patient in the ICU.
4. Risk factors for Clostridium difficile infection
Risk factors for C. difficile infection fall under three categories. First category includes disrup-
tions of the endogenous intestinal flora, perturbations of the mucosa, or immunomodulation 
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by exogenous factors that can occur as a result of medications, procedures, or radiation 
therapy. Most hospitalized patients with C. difficile infection have been exposed to antibi-
otics within the past 30 days. More recently, it has been noted that medications that sup-
press gastric acid, including proton-pump inhibitors and H
2
-receptor blockers, increase risk 
of C. difficile infection, though study results are not uniform and the mechanism is not known 
[50–54]. For patients with primary or recurrent C. difficile infection, consideration should be 
given to discontinuation of gastric acid suppressants unless the patient’s risk for GI bleeding 
outweighs the risk of C. difficile infection treatment failure. Chemotherapy, medications for 
autoimmune conditions, transplant medications, and radiation of the bowel increase the risk 
of C. difficile infection by disrupting the normal intestinal mucosal barrier and inhibiting the 
body’s immunodefenses. Nasogastric tubes and enemas, presumably because of alteration of 
the normal flora and/or pH, increase patients’ risk of C. difficile infection [55].
The second category of risk factors relates to how patients contract C. difficile infection. The 
most common method is by coming in contact with C. difficile spores from the hands of 
health care workers. Risk of contracting C. difficile infection is directly related to length of 
stay (LOS). Patients with longer LOS have multifactorial risk factors that include more severe 
illnesses that have a higher likelihood that they will require antibiotics and more prolonged 
exposure and interactions with health care workers [56, 57]. A patient’s risk of contracting 
C. difficile infection is also related to C. difficile infection pressure that relates to the number of 
patients with C. difficile infection in a given care area [58]. Certain C. difficile strains, including 
the epidemic BI/NAP1/027 strain, have been isolated from prepared foods, pets, and from 
livestock [59–61].
The third category of risk factors relates to innate host susceptibility. Age >65 years is 
related to both an increased risk of primary C. difficile infection as well as an increased 
risk of more severe C. difficile infection. It is not known whether this is related to immune 
senescence, more frequent antibiotic usage, or increased comorbidities. The four comor-
bidities that place patients at greatest risk are sepsis, pneumonia, urinary tract infections, 
and skin infections—all of which generally require antibiotics for treatment. Patients hos-
pitalized with higher numbers of conditions are more likely to contract C. difficile infection 
than patients with fewer conditions [48]. More recently, it has been noted that peripartum 
women and infants also appear to be at increased risk for C. difficile infection, including 
severe C. difficile infection related to the epidemic BI/NAP1/027 strain [62, 63]. Patients with 
inflammatory bowel disease (IBD) are more susceptible to C. difficile infection for reasons 
that are likely multifactorial, including antibiotic exposure, altered gut mucosal integrity, 
and immunosuppressive therapy. Patients with C. difficile infection superimposed on a flare 
of IBD are at risk for a particularly fulminant course. Because of altered gut physiology, 
patients with IBD may not develop pseudomembranes and may have a complicated diag-
nosis. Additionally, administration of glucocorticoids to treat the IBD exacerbation may 
predispose to C. difficile infection progression [64, 65]. Studies have shown that patients 
with HIV/AIDS or chronic kidney disease requiring hemodialysis are also at increased risk 
of C. difficile infection, possibly due to increased health care worker exposure or less robust 
immune response [66, 67].




In the modern era, multiple tools have been developed to identify and detect C. difficile to 
include cultures, polymerase chain reaction (PCR), and enzyme immunoassays (EIA). 
Culturing C. difficile is difficult due to the strict anaerobic nature of the organism and the 
oxygen sensitivity that can kill the living organism. Utilizing an anaerobic chamber with a 




, and 85% N
2, 
along with an air lock, has allowed the cultur-
ing, preservation, and storage of the living organism and spores [35, 43]. Once the organism 
has been cultured, PCR or EIA techniques can be utilized to detect toxin within the culture. 
These same techniques can be used independently of a culture to detect toxin within the 
stool sample. PCR has been successfully used since 1985 to amplify the 8.1 kilo base-pairs of 
the toxin A gene. Using 35 cycles of alternating 95–55°C temperatures and a Southern blot to 
isolate the 252 base-pair DNA fragment, PCR has become easy and commonplace for identi-
fication of the toxins [40, 41]. EIA has similarly been used since the early 80s for detection of 
both toxin A and B. The early tests were able to detect levels of toxin to 0.1 ng using a double 
sandwich microtiter plate with specificities of 98.6% and 100% for toxin A and toxin B, respec-
tively [42–45]. More recently, glutamate dehydrogenase-immunoassay has been used as an 
initial screening tool with a chemiluminescent toxin-immunoassay for confirmation of both 
toxins A and B. The combined two-step process has a sensitivity and specificity of 100% [68]. 
The premise of the EIA tests is that antibodies to the toxins are attached to a plate. When the 
toxins pass over the antibodies, they become bound. A second preparation of antibodies with 
a marker attached to them is then added and a device to detect the markers allows for quan-
titative evaluation of the toxins present.
Figure 2. Clostridium difficile associated pseudomembranous colitis. Credit: North American Society for Pediatric Gastro-
enterology, Hepatology and Nutrition.
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In addition to laboratory tests, computed tomography is useful to evaluate for toxic mega-
colon and colitis. When there is high clinical suspicion yet laboratory diagnostic tests have 
yielded negative results, the definitive test is colonoscopy. The appearance of pseudomem-
branes in the clinical setting of C. difficile infection is confirmatory for the diagnosis (Figure 2). 
Table 1 displays the various current diagnostic modalities.
Intensivists should be familiar with the tests offered in their institution and be able to inter-
pret the laboratory results in the context of clinical presentation. When clinical suspicion for 
C. difficile infection is high, the intensivist should initiate empiric therapy for C. difficile infec-
tion regardless of the diagnostic test results [48].
6. Treatment
Once diagnosed, the first line of treatment is to discontinue implicated antibiotics, gastric 
acid suppression medications, and antiperistaltic medications, including narcotics and anti-
motility agents. Reduced peristalsis may prolong toxin exposure to the colonic mucosa [7]. 
Unfortunately, a large proportion of patients who develop C. difficile infection have docu-
mented infections that require treatment with antibiotics, and in the ICU setting, this propor-
tion may reach 60% [69]. When it is not possible to stop antibiotic therapy, it is best to tailor 
coverage to more narrow spectrum agents once cultures and sensitivities are available. It is 
recommended to transition as soon as possible to β-lactams, macrolides, aminoglycosides, anti-
staphylococcal drugs, tetracyclines, and other agents that have a lower likelihood of causing 
C. difficile infection [70].
Test Detection Time Usefulness
Culture Clostridium difficile 34 days Nonspecific and not useful for detection of toxins
Culture-toxins Toxigenic Clostridium 
difficile
3–4 days Must have initial growth from culture prior to testing for 
toxins
Cytotoxin Toxin B 2–3 days Costly and time-consuming. Results not immediately 
available
EIA toxin A & B Toxin A & B 2–3 hours Very quick but not sensitive. Need 3 specimens for 
increased sensitivity
EIA GDH Clostridium difficile 2–3 hours Screening test. Detects presence of bacteria but not specific
Toxin B gene Toxigenic Clostridium 
difficile
2–3 hours Very sensitive for detection of toxigenic strains of 
Clostridium difficile using PCR
Colonoscopy Pseudomembranes <1 hour Very specific and sensitive for the detection of 
pseudomembranes
CT scan Colitis <1 hour Very sensitive for colitis but not specific for Clostridium 
difficile infections
EIA, Enzyme Immunoassay; GDH, glutamine dehydrogenase; PCR, polymerase chain reaction; CT, computed tomography
Table 1. Diagnostic modalities for the identification of Clostridium difficile in the ICU.
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Oral vancomycin is the only agent currently approved for treatment of C. difficile infection, 
although metronidazole in both oral and intravenous forms has been shown to be effective 
in treating C. difficile infection. Intravenous vancomycin has not been shown to be effective. 
Metronidazole has become the preferred agent for initial treatment of C. difficile infection 
because of lower cost [71, 72] and because of concerns over the possibility of increased 
development of vancomycin-resistant enterococcus [73, 74]. Metronidazole should be con-
sidered first-line therapy for mild to moderate C. difficile infection; however, it does have dis-
advantages compared to oral vancomycin. In a study involving 207 patients with C. difficile 
infection, 22% of patients remained symptomatic after 10 day therapy with metronidazole 
and 27% developed a relapse [75]. In a separate randomized trial involving 150 patients, the 
cure rate for metronidazole was only 76% compared with a 97% cure rate after treatment 
with vancomycin for the treatment of severe C. difficile infection [49]. Based on these studies 
and other data, oral vancomycin should be considered superior in the treatment of severe 
infections when GI motility is intact (Table 2) [49]. The pharmacology of oral vancomycin 
lends itself to being more effective as it is not absorbed by the GI tract and reaches the colon 
in high concentrations. The usual dosing regimen of 125 mg achieves levels of vancomycin 
500–1000 times the minimal inhibitory concentration (MIC) of 90% of C. difficile in stool [48].
If the patient has ileus or severe pseudomembranous colitis and medication cannot be given 
orally, the use of rectal instillation of vancomycin solutions is supported by case reports [70, 
76, 77]. The addition of intravenous metronidazole to either oral or intracolonic vancomycin 
in severely ill patients with ileus has been described, although this approach has not been 
adequately studied [78, 79].
Fidaxomicin is the first member in a new class of narrow spectrum macrocyclic antibiotics that 
are enterally administered and minimally absorbed in the GI tract. Having excellent in vitro 
and in vivo activity against C. difficile, including NAP1/BI/027 strains, and, while exhibiting 
limited activity in vitro and in vivo against components of the normal gut flora, fidaxomicin is 
an excellent candidate for replacing other agents in the treatment of C. difficile infections [80]. 
In a prospective, multicenter, double-blind, randomized, parallel-group trial involving 596 
Severity Preference Medications
Mild CDI 1st line
Alternate (PO)
Alternate (IV)
Metronidazole: 500 mg PO every 8 hours
Vancomycin: 125 mg PO every 6 hours or Fidaxomicin: 200 mg PO every 12 
hours
Metronidazole: 500 mg IV every 8 hours
Severe CDI 1st line
Alternate (IV)
Vancomycin: 125 mg PO every 6 hours
Metronidazole: 500 mg IV every 8 hours
Life-threatening CDI 1st line Vancomycin: 500 mg every 6 hours via NGT or by enema plus
Metronidazole: 500 mg IV every 8 hours
Relapsed CDI 1st line Treatment based on severity as above
Table 2. Treatment modalities for Clostridium difficile infections.
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patients, of which 287 received fidaxomicin and 309 received vancomycin, 88.2% of patients in 
the fidaxomicin group and 85.8% of those in the vancomycin group met the criteria for clinical 
cure. In addition, treatment with fidaxomicin was associated with a significantly lower rate of 
recurrence than was treatment with vancomycin (15.4 vs. 25.3%). More studies are warranted 
but results are promising [49, 81, 82].
Regardless of the type of medication, early treatment has been supported as the most effec-
tive pharmacologic treatment. A study by Zahar et al. conducted in three French ICUs has 
demonstrated that early treatment of ICU-acquired C. difficile infection results in mortality 
rates consistent with a control population of other ICU patients that have developed diarrhea 
that is not C. difficile infection associated. Treatment was initiated within 24 hours of onset 
and consisted of either metronidazole or oral vancomycin. The study involved 5,260 patients 
with an incidence of ICU-acquired diarrhea of 9.7%. All those with diarrhea were tested for 
C. difficile infection and 13.5% of those tested had confirmed toxin A or B by EIA and further 
confirmation by culture. None of the positive cultures produced any of the hypervirulent 
NAP1/027 strains seen in North American outbreaks. Overall mortality of ICU-acquired 
C. difficile infection was not independently associated with higher mortality rates compared 
to other patients with diarrhea in the ICU when matched for severity of illness, comorbidi-
ties, or complications occurring in the ICU. However, both the overall hospital stay and ICU 
stay was prolonged in the ICU-acquired C. difficile infection patients when compared to ICU 
patients as a whole (median 4 vs. 20 days) and ICU patients with diarrhea not associated 
with C. difficile infection (median 17 vs. 20 days). Despite these prolonged median stays, 
analysis did not demonstrate a statistically significant difference in length of stay with an 
estimated increase in overall ICU stay of 6.3 days ± 4.3, p = 0.14 compared to other ICU 
patients with diarrhea [83].
Microbial therapy with fecal transplantation can be accomplished with instillation of liquid 
preparations of stool from healthy donors. This method has proven successful for treat-
ing recurrent C. difficile infection in 70–100% of cases [84]. Probiotics may prevent attach-
ment of C. difficile to epithelial cells and can reduce the incidence of C. difficile infection. 
Saccharomyces boulardii in particular has proven to be effective [49] whereas the use of 
Lactobacillus with conventional antibiotic therapy has shown mixed results including some 
studies showing no benefit in the treatment of C. difficile infection in several randomized 
controlled trials [85–88].
Use of anion exchange resins, such as cholestyramine and colestipol, with the hope of bind-
ing C. difficile cytotoxins in the treatment of C. difficile infection, has not only been shown to 
be effective [89, 90], but also carries the theoretical risk of binding intraluminal vancomycin, 
thus resulting in subtherapeutic vancomycin levels [91]. Intravenous immunoglobulins have 
been suggested for treatment of C. difficile infection but due to an insufficient evidence base 
and conflicting data, its use cannot be generally recommended until further studies have been 
conducted [92, 93]. Subtotal colectomy should be considered if there is no response to medical 
therapy within 3–4 days or if the patient remains seriously ill to avoid complications such as 
colonic perforation and sepsis [7].
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7. Treatment failure and relapse
Patient characteristics that predispose to metronidazole failure include low serum albumin, 
continued exposure to the inciting antibiotic, and residence in the ICU [94, 95]. Particularly 
worrisome and concerning is the finding that relapsing or recurrent infections occur in up to 
30% of patients treated for C. difficile infection whether the initial treatment was metronida-
zole or vancomycin [96]. This could be due to reinfection with the same endogenous strain or 
from a different strain acquired exogenously. Patients that had an initial infection followed 
by reinfection have a 50–65% chance of further repeated episodes. A metaanalysis by Garey 
et al. found that reexposure to antimicrobials, gastric acid suppression, and older age are 
all associated with an increased risk of recurrent C. difficile infection [97]. Patients that have 
three or more episodes of C. difficile infection, considered to be multiple C. difficile infection 
recurrence, are best treated with a tapered regimen of oral vancomycin. The initial dose of 
vancomycin administered is at the usual 125 mg by mouth four times a day for 10–14 days 
but then one dose per day is removed one week at a time until the patient is taking one dose 
every 2–3 days. The rationale for this regimen is that as the doses are spaced out, the colonic 
flora has time to regenerate [48].
8. Generating optimal colonic flora for risk reduction
There is an urgent need for alternative means of preventing and treating C. difficile infection in 
high-risk individuals. Metagenomics have improved our understanding of the “colonization 
resistance barrier” and how this could be optimized. The “colonization resistance barrier” 
in the normal healthy colon consists of high microbial diversity, substrate/area competition, 
immune response modulation and short-chain fatty acid (SCFA) production [16, 98]. These 
factors are often missing in the elderly. Decreased pH, oxidation-reduction potentials, and 
higher concentrations of short-chain fatty acids have been suggested to inhibit C. difficile 
growth and toxin production throughout in vitro and in vivo studies. There is, therefore, evi-
dence in support of a colonization resistance barrier against C. difficile infection [16, 98].
For instance, in vitro, Bifidobacterium longum and Bifidobacterium breve have been show to sig-
nificantly reduce the growth of the toxigenic strain C. difficile LMG21717 [99]. In a randomized, 
placebo-controlled, double-blind trial at a long-term elderly care facility, the effectiveness 
of a Lactobacillus casei strain Shirota (LcS) infused beverage was demonstrated by altering 
Clostridium infection rates among the residents. Daily consumption of the beverage resulted 
in a significantly lower incidence of fever and improved bowel movements. When compared 
to a resident control group drinking a placebo beverage, stool studies from the experimental 
LcS group showed significantly higher number of both Bifidobacterium and Lactobacillus 
(p < 0.01), significantly lower number of destructive bacteria such as C. difficile (p < 0.05), and 
a higher fecal acetic acid concentration. This study was also conducted among the facility’s 
staff and a significant difference in the intestinal microbiota, fecal acetic acid, and pH was also 
observed between the LcS and placebo groups [100].
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There is some evidence to support that plant based diets may reduce the number of patho-
bionts such as C. difficile and increase the number of protective species such as Lactobacillus 
[100–103]. Altered flora with resulting altered bile metabolism within the gut by flora favored 
by plant-based diets have implications in colonocyte protection [102]. Intestinal microbiota 
are able to produce short chain fatty acids (SCFA), such as acetate, propionate, and butyrate, 
through metabolism of dietary fiber. These SCFA have been shown to be colonocyte protective. 
A strong positive correlation has been found between Faecalibacterium prausnitzii and butyrate 
production in the gastrointestinal tract, suggesting that this species may be associated with 
higher fiber intake and reduced risk, not only for C. difficile infection, but also for other common 
comorbidities in the elderly including cardiovascular disease, colon cancer, diabetes, and obe-
sity [104]. A move toward a diet that decreases risk for contracting C. difficile infection should 
be encouraged, not only in the elderly, but also generally, because of the broad implications.
9. Prevention of hospital spread
Disinfectant products based on quaternary ammonium compounds, commonly used to clean 
patient rooms, are not sporicidal. Therefore, using sporicidal hypochlorite-based disinfec-
tants on surfaces is recommended. However, use of antisporicidal agents outside an outbreak 
is not associated with lower rates of C. difficile infection [105, 106].
Hand hygiene is the most important preventive measure to reduce transmission of C. difficile 
spores. Soap and water has been demonstrated to be superior to alcohol based hand rubs and 
other forms of hand sanitation with regard to transmission by healthcare workers [21, 107]. 
Hospital hygiene hand protocols should be followed assiduously at all times. Other precau-
tions that should be utilized include isolation of the patient, barrier precautions, and use of 
chlorine based chemical wipes [107]. These precautions should not be lifted based on stool 
studies as there are no diagnostic methods to determine response to treatment. Rather, the deci-
sion should be made on clinical signs and symptoms with resolution of diarrhea, fevers, and 
leukocytosis. A strong antibiotic stewardship program is essential to limit the use of antibiot-
ics that may cause C. difficile infection and is generally a good principle to follow. It has been 
demonstrated that up to 25% of antibiotic administration is not indicated, even in the ICU [108].
10. Clostridium difficile infection in the intensive care unit
Diarrhea is a common problem in the ICU affecting up to 40% of patients admitted. Severely 
burned patients may have an incidence of greater than 90% [109, 110]. Enteral tube feeding is 
the most common cause of diarrhea in the ICU; other causes include hypoalbuminemia, intes-
tinal ischemia, and medications. C. difficile infection is the most common infectious cause of 
diarrhea in the ICU [111, 112]. The severity of C. difficile infection is increasing which is possibly 
related to the emergence of more virulent strains such as the BI/NAP1/027 strain, prompting 
more admissions to the ICU for management of C. difficile infection related complications [113].
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In a systematic review and metaanalysis of 22 published studies from 1983 to 2015 that 
included 80,835 ICU patients, the effects of C. difficile infection on morbidity and mortality 
were investigated. Karanika et al. found that prevalence of C. difficile infection among ICU 
patients was 2% but 5-fold greater in those patients with diarrhea (11%). Those patients that 
were diagnosed with C. difficile infection had a 25% incidence of the severe form of the disease 
and diagnosed with pseudomembranous colitis. ICU mortality was not significantly different 
between the group with C. difficile infection and the nonC. difficile infection group based on 
seven studies that enrolled a combined 12,165 patients. However, the overall hospital mortal-
ity between those same groups was significantly increased in the C. difficile infection group 
with 32% mortality compared to 24% (p = 0.03). Similarly, length of ICU and hospital stay 
among C. difficile infection patients was longer when compared to nonC. difficile infection 
patients. Based on five studies with over 10,000 patients, C. difficile infection patients had an 
average ICU stay of 24 days and overall hospital stay of 50 days compared to 19 days and 30 
days, respectively, for the nonC. difficile infection group (p = 0.001) [114].
Even though only 3% of patients with C. difficile infection require subtotal colectomy for ful-
minant C. difficile colitis, 20% of ICU patients with severe C. difficile infection will still require 
partial colectomy or diversion [115, 116]. Colectomy in this setting is associated with a 50% mor-
tality [90]. Mortality rates are lower when surgical intervention is undertaken within 48 hours 
of lack of response to medical therapy [117]. During NAP1/027 outbreaks, patients with age >65 
years, leukocytosis and elevated lactate appear to benefit the most from early colectomy [118].
In a series of 29 patients with severe or severe/complicated C. difficile infection refractory to 
oral vancomycin ± rectal vancomycin and intravenous metronidazole therapy who under-
went fecal microbiota transplantation (FMT) plus continued vancomycin, overall treatment 
response was 93% (27/29), including 100% (10/10) for severe C. difficile infection and 89% (17/19) 
for severe/complicated C. difficile infection. A single FMT was performed in 62%, two FMTs 
were performed in 31%, and three FMTs in 7% of patients. Continued use of non C.  difficile 
infection antibiotics predicted repeat FMT. Thirty-day all-cause mortality after FMT was 7%. 
Of the two patients who died within 30 days, one underwent colectomy and  succumbed to 
sepsis; the other died from septic shock related to C. difficile infection [84]. Further research 
into the use of FMT combined with continued vancomycin is needed.
11. Modern outbreaks
In 2003, a major outbreak of C. difficile occurred in Quebec, Canada and was identified as ribo-
type 027, strain BI/NAP1. This strain has been identified in >50% of all isolates from hospitals 
in Europe and North America [4, 10, 20]. Prior to the 2003 outbreak, this strain only accounted 
for 14 of over 6000 (<0.02%) typed strains collected from U.S. cases during the period of 1984 
to 1993. Following the 2003 outbreak in Canada, 96 of 187 (51%) strains tested positive for 027 
in eight U.S. outbreaks [119].
The BI/NAP1/027 strain belongs to a hypervirulent group of strains along with types 001, 
017, and 078. In particular, the binary toxin produced by 027 was not seen previously. It is 
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thought to be synergistic with the production of toxin A and B. Strain BI/NAP1/027 was found 
to be highly resistant to fluoroquinolone classes of antibiotics and was also found to produce 
16-fold higher concentrations of toxin A and 23-fold higher concentrations of toxin B than less 
virulent toxinotype 0 strains. The binary toxin has been associated with more severe diarrhea 
when combined with toxin A and B. When produced alone, binary toxin does not appear to 
produce disease [3, 10] but does appear to be a marker of both C. difficile infection severity 
and recurrence [120]. The emergence is generally believed to be related to fluoroquinolone 
exposure though not to the particular type of fluoroquinolone [121, 122].
12. Conclusions
C. difficile is a very diverse group of toxin producing organisms. Newer technologies have 
allowed the identification of numerous toxinotypes and ribotypes with varying virulence 
factors and toxin production. Multiple lineages contain hypervirulent strains. The large 
degree of horizontal gene transfer through transposons, bacteriophages, and homologous 
recombination has dispersed genetic material and pathogenic properties among different 
strains.
The increased prevalence of ribotypes 027, 017, and 078 may be solely due to population 
expansion over the last decade or due to a nosocomial enrichment of the proper environment 
and conditions for the expansion and transference of these virulent strains. The sudden rise 
may also be related to the delay in purifying selection pressures seen in the more recently 
diverging lineages. However, a more likely explanation for increasing incidence is the right 
combination of elderly patients in a contaminated environment with antibiotic and acid sup-
pression medications. Given the high incidence of colonized guts in the hospitalized pediatric 
population (70%), the hospitalized adult population (25%), the animal kingdom (40%), and 
the natural environment (50%), reducing exposure is near impossible [14].
The high virulence, along with a highly mobile genome capable of antibiotic resistance, 
has prompted further research in the development of vaccinations. Sanofi-Aventis is cur-
rently undergoing trials with a vaccine containing formalin-inactivated toxins A and B. 
To date, 100 healthy subjects have been exposed to the vaccine without any serious side 
effects [123].
The hardiness of C. difficile spores and the ease with which this bacterium alters its genome 
has allowed it to flourish and survive among a variety of hosts and reservoirs. More virulent 
strains are a real possibility given the mobility of code sequencing regions within the genome. 
As the population continues to age and makes an increasingly stronger presence through-
out the healthcare system, especially in the ICU, C. difficile will continue to plague patients 
and healthcare providers until further measures are discovered to control transmission. The 
increased burden will stress the current resources and facilities financially, geographically, 
and the pool of available care takers. To date, the best treatment modalities include eliminat-
ing the implicated antibiotics, early initiation of oral vancomycin and metronidazole, and 
strict infection-control engineering to prevent the initial infection.
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